Axillary Hyperhidrosis Treatment Market is projected to exhibit a CAGR of 6.7%, and cross a worth of US$ 3.3 Billion by forecast ending 2033 | Future Market Insights, Inc.
01. Mai 2023 20:30 ET
|
Future Market Insights Global and Consulting Pvt. Ltd.
NEWARK, Del, May 01, 2023 (GLOBE NEWSWIRE) -- As per Future Market Insights’ latest industry analysis, the valuation for the global axillary hyperhidrosis treatment market was around US$ 1.6 Billion...
Dermira and Christian Siriano Collaborate to Inspire People Living with Excessive Underarm Sweating to Feel Confident in Their Own Skin
02. Oktober 2018 08:30 ET
|
Dermira, Inc.
Mr. Siriano invites the millions of people living with hyperhidrosis in the U.S. to share their ‘sweat stories’ MENLO PARK, Calif., Oct. 02, 2018 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ: DERM), a...
Newly Published Nonclinical Data Highlight the Role of Olumacostat Glasaretil in Sebum Inhibition
26. Juni 2017 07:30 ET
|
Dermira, Inc.
MENLO PARK, Calif., June 26, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering...
Dermira Announces Appointment of Ian Clements as Vice President, Investor Relations
06. Juni 2017 07:30 ET
|
Dermira, Inc.
MENLO PARK, Calif., June 06, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering...
Dermira to Present at Jefferies 2017 Global Healthcare Conference
30. Mai 2017 16:05 ET
|
Dermira, Inc.
MENLO PARK, Calif., May 30, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering...
Dermira Announces Closing of 3.00% Convertible Senior Notes Offering
16. Mai 2017 16:01 ET
|
Dermira, Inc.
MENLO PARK, Calif., May 16, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM) announced today the closing of its previously announced offering of 3.00% Convertible Senior Notes due 2022 (the...
Dermira Prices Offering of $250 Million of 3.00% Convertible Senior Notes
10. Mai 2017 21:32 ET
|
Dermira, Inc.
MENLO PARK, Calif., May 10, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM) announced today the pricing of its offering of $250,000,000 aggregate principal amount of 3.00% Convertible Senior...
Dermira Announces Proposed Offering of $250 Million of Convertible Senior Notes
09. Mai 2017 16:01 ET
|
Dermira, Inc.
MENLO PARK, Calif., May 09, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM) announced today that it intends to offer, subject to market conditions and other factors, $250,000,000 aggregate...
Dermira Reports First Quarter 2017 Financial Results and Provides Corporate Update
08. Mai 2017 16:08 ET
|
Dermira, Inc.
-Submissions for CIMZIA® (certolizumab pegol) and glycopyrronium tosylate remain on schedule for later this year MENLO PARK, Calif., May 08, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a...
Dermira to Present at Needham 16th Annual Healthcare Conference
28. März 2017 16:05 ET
|
Dermira, Inc.
MENLO PARK, Calif., March 28, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering...